Highlights: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Read more
Unlock the Potential of Advanced Nanotechnologies
What We Do
At LamdaGen, we are committed to reshaping the field of advanced plasmonics by delivering innovative biodetection solutions tailored to meet the critical demands of various industries. Our plasmonic technologies enable the creation of simple, advanced and cost-effective detection systems that redefine speed and precision. Our robust and adaptable plasmonic biosensors support a range of applications, including human and animal health, food and water safety, biothreat detection, and environmental monitoring.
The LAuRA™ platform, powered by LamdaGen’s Plasmonic Amplification Technology™ (PAT™), exemplifies our commitment to enhancing diagnostic and detection capabilities. We utilize our well-established plasmonic systems to improve the sensitivity and precision of diagnostic tools, directly supporting applications in health, safety and monitoring sectors.
We pride ourselves on fostering close collaborations with our partners and clients, ensuring the seamless integration of our plasmonic technologies into their research, development, services and products. Through a commitment to technological excellence and practical application, LamdaGen utilizes a licensing model to distribute our advanced plasmonic detection solutions across varied sectors.
LAuRA™ Plasmonic Sensing, powered by PAT™
Fast Results
High Sensitivity
Patented Technology
Easy to Integrate
Easy to Use
LAuRA Rapid Test System
LAuRA (LamdaGen Au (gold) Rapid Assay) offers a turnkey plasmonic biosensing solution, combining the speed and convenience of lateral flow assays with the high sensitivity and quantitation of ELISA tests.
The LAuRA Rapid Test System delivers laboratory quality results equivalent to gold standard ELISA’s in minutes rather than hours. LAuRA’s test procedure is simple and easy to use. Disposable cartridges can be designed to run single or multi-target tests and deliver results 15 minutes or less.
Leveraging the inherent properties of advanced nano-based plasmonics, the LAuRA immuno-based platform provides high sensitivity detection capabilities far exceeding those of existing rapid assays. The patented platform is flexible and scalable, enabling uniquely powerful detection systems ranging from small benchtops to handhelds to throughput.
Innovative LAuRA systems are being developed for applications in Human Health, Food & Water Safety, Biothreat Detection, and Animal Health.
What would you like to learn?
LAuRA, powered by PAT harnesses the unique properties of plasmonics to revolutionize diagnostic detection
See how LAuRA delivers results with speed, sensitivity and convenience like no other platform
LamdaGen is taking a One Health approach to improve the performance and accessibility of rapid testing
Latest News
LamdaGen Corporation, a developer of nano-based plasmonic biosensor technology has entered into a subcontract with MRIGlobal and JPEO-CBRND to undertake proof-of-concept studies for the detection of a priority biothreat using immobilized phage receptor-binding proteins...
LamdaGen Corporation, an emerging diagnostic technology company with a powerful, plasmonic platform for rapid diagnostic/detection testing, is pleased to announce the members of its newly-formed Strategic Advisory Board (SAB).
The inaugural SAB members represent a distinguished set of experts who bring a depth and breadth of leadership, innovation and product commercialization experience in the life science, diagnostic, pharmaceutical and food safety industries.
This brief describes the optical properties of LamdaGen’s gold plasmonic sensor surfaces compared to the optical properties of gold (Au) colloids. As we will show, the plasmonic films are superior to gold colloidal solutions for biosensing. In fact, the optical properties of the plasmonic films match those of single Au nano-rods, one of the most sensitive techniques for biosensing as interrogated a single particle at a time. While biosensing at the single molecule level poses enormous challenges commercially, the patented manufacturing process of LamdaGen’s continuous nano-structured thin-films is highly reproducible, scalable and economic. Thus, the plasmonic films bring the benefits of the nanoscopic world into the commercial realm.
LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the Indian Patent Office has granted and recorded patent 360405 titled ENZYMATIC ASSAY FOR LSPR which enables
MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the United States Patent and Trademark Office has given Official Notice
MENLO PARK, CA, January 8, 2021— LamdaGen Corporation, a developer of plasmonic biosensor systems for diagnostics, announced the Japanese Patent Office has given Official Notice of Allowance to its patent application entitled MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS which enables high
The viral load of SARS-CoV-2 in patients charted as determined in hospital settings across several regions of the world.[1-4] In three studies, the pool includes a limited number patients with mild to moderate symptoms in hospitals,
Interested in our biosensors & collaborative opportunities?
Contact us to explore how our detection technologies can benefit your R&D, Services and Product objectives.
Let’s discuss possibilities and drive innovation together.
